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Abstract 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The aim of this project was, primarily, to clone, express and 
investigate the function of a cfr-like gene from Clostridium 
sporogenes (clcs) in E. coli and, subsequently, to investigate the 
function of the clcs gene in C. sporogenes, its natural host, and 
ascertain possible variations in function. The cfr and cfr-like 
genes were cloned into a plasmid, which allowed their 
constitutive expression in E. coli. The ClCs protein was not able 
to mediate changes in the antibiotic susceptibility of E. coli 
compared to the PhLOPSA phenotype conferred by the Cfr 
methyltransferase. The lack of function of the expressed protein 
was also investigated by combining parts of the cfr and clcs 
genes, but no MIC changes were observed. Attending to the Cfr 
methyltransferase function, the verification of the presence or 
absence of the RNA methylation at A2503 in 23S rRNA from E. 
coli was checked by primer extension, showing that the ClCs-
containing strain E. coli JW2501-1 does not give rise to any stop 
at A2503, revealing that the Cfr-like protein from C. sporogenes 
does not methylate E. coli 23S RNA, which is consistent with the 
MIC results. Since it was not possible to conclude that ClCs does 
not have a Cfr-like function, further investigation was required 
to determine if ClCs could be able to methylate C. sporogenes 
23S RNA and act as Cfr. 
Two C. sporogenes strains reported as cfr-like gene carriers were 
investigated. The attempts to amplify the cfr-like genes revealed 
that the assumption that both these C. sporogenes strains 
contained a cfr-like gene seemed to be true for only one of them.  
MICs showed that the cfr-like gene-containing C. sporogenes 
strain has lower susceptibility to all the PhLOPSA antibiotics 
tested than the presumably Cfr-lacking C. sporogenes strain. The 
uncertain function of the ClCs protein was then investigated by 
primer extension to look for an indication of modification at 
A2503 23S RNA from C. sporogenes (E. coli numbering). As a 
similar stop was observed for both strains, mass spectrometry 
was performed revealing a mono-methylation at A2503, 
probably caused by the housekeeping RlmN protein and not by 
Cfr. Another possible modification in the area around A2503 was 
detected and should be further analyzed. 
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Resumo 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
O objectivo deste projeto foi, inicialmente, clonar, expressar e 
investigar a função de um gene cfr-like de Clostridium 
sporogenes (clcs) em E. coli e, posteriormente, investigar a 
função do gene clcs em C. sporogenes, o seu hospedeiro original, 
verificando possíveis variações na sua função. Os genes cfr e cfr-
like foram clonados num plasmídeo, o que permitiu a expressão 
constitutiva dos genes em E. coli. A proteína ClCs não mediou 
alterações na susceptibilidade de E. coli aos antibióticos, em 
comparação com o fenótipo PhLOPSA conferido pela 
metiltransferase Cfr. A ausência de função das proteínas 
expressas foi também investigada através da combinação de 
partes dos genes cfr e clcs, contudo não foram observadas 
alterações nas MICs. Tendo em conta a função da 
metiltransferase Cfr, a verificação da presença ou ausência da 
metilação na posição A2503 do rRNA 23S de E. coli foi analisada 
por primer extension, mostrando que a estirpe E. coli JW2501-1 
que compreende a proteína ClCs não dá origem a qualquer stop 
na posição A2503, demonstrando que a proteína Cfr-like de C. 
sporogenes não metila o RNA 23S de E. coli,  o que é consistente 
com os resultados das MICs. Uma vez que não foi possível 
concluir que a proteína ClCs não possui a função de uma 
proteína Cfr-like, foi necessária uma investigação mais 
aprofundada para determinar se a proteína ClCs poderia metilar 
o RNA 23S de C. sporogenes e funcionar como Cfr. 
Duas estirpes de C. sporogenes apontadas como portadoras do 
gene cfr-like foram investigadas. As tentativas para amplificar os 
genes cfr-like revelaram que a hipótese de ambas as estirpes 
conterem um gene  cfr-like parecia ser verdade para apenas uma 
delas. As MICs mostraram que a estripe C. sporogenes que 
compreende o gene cfr-like tem menor susceptibilidade a todos 
os antibióticos PhLOPSA testados do que a presumível estirpe de 
C. sporogenes que não possui a proteína Cfr. A função dúbia da 
proteína ClCs foi então investigada por primer extension na 
tentativa de encontrar alguma modificação na posição A2503 do 
RNA 23S de C. sporogenes (numeração em E. coli). Como foi 
observado um stop semelhante em ambas as estirpes, foi 
realizada espectrometria de massa, revelando uma mono-
metilação na posição A2503, provavelmente causada pela 
proteína housekeeping RlmN e não pela Cfr. Uma outra possível 
modificação em torno da posição A2503 foi detectada e deverá 
ser posteriormente analisada. 
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1. Introduction 
1.1. Antibiotic resistance in bacteria 
The discovery of antibiotics in the early part of the last century completely altered the 
treatment of common infections, and it was almost taken for granted by the patients that infections 
would be diagnosed and immediately treated [1]. However, almost as soon as antibacterial drugs 
were released, bacteria were able to evolve and become resistant to antibiotics, revealing various 
forms of resistance, such as mutation and acquisition of new DNA, inactivation of the drugs or 
reduction of their access to the sites of action, and modifying the drug target [2]. The mechanisms 
that will predominate depend on the nature of the antibiotic, its target site, the bacterial species 
and if it is mediated by a resistance plasmid or by a chromosomal mutation [3].  
Most antibiotics can be classified according to their main mechanism of action: interference 
with cell wall synthesis, inhibition of protein synthesis, interference with nucleic acid synthesis, and 
inhibition of a metabolic pathway [4]. A wide range of antibiotics affect protein synthesis by 
modification of the specific target [3]. One of the most preferred targets is the ribosome. The 
bacterial ribosome is disturbed by the antibiotics at crucial components, interfering with the 
synthesis of new proteins [5]. Ribosomes (sedimentation coefficient of 70S) are large RNA-proteins 
complexes and comprise of a small (30S) and a large (50S) subunits: the small subunit decodes the 
genetic information mediating the interaction between transfer RNA (tRNA) and messenger RNA 
(mRNA), and the large subunit catalyses peptide bond formation. Many antibiotic classes bind to 
the 16S ribosomal RNA (rRNA) in the 30S ribosomal subunit (aminoglycosides and tetracyclines, for 
example) or to the 23S rRNA in the 50S ribosomal subunit (oxazolidinones, macrolides, 
lincosamides, among others) [6-8]. The large subunit is targeted by an extensive range of drugs that 
interfere with GTP hydrolysis (substrate for the synthesis of RNA), formation of peptide bonds, and 
channelling the peptide through the exit tunnel, interfering with tRNA transition between the 
binding sites located within the tunnel that crosses the two subunits. Three tRNA binding sites were 
identified and characterized: the aminoacyl (A), peptidyl (P), and exit (E) sites. On these subunits, 
most of the antibiotic binding sites cluster at or near the peptidyl transferase centre (PTC), where 
peptide-bond formation occurs (Table 1, Figure 1A).  PTC comprises of two major components: the 
A site, which interacts with the CCA end of aminoacylated tRNAs, and the P site, where the CCA 
ends of peptidyl tRNAs are bound when peptide bonds form. PTC-targeting antibiotics inhibit 
peptide-bond formation by perturbing or preventing the correct positioning of the aminoacylated 
ends of tRNAs in the PTC. The binding sites of PTC-targeting antibiotics overlap with the A-site tRNA 
or with the P-site tRNA, or span both the A- and P-sites (Figure 1B) [5, 9-11].  
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Table 1: Mechanisms of action and resistance mechanisms of selected 50S subunit-targeting antibiotics [11]. 
Antibiotic Inhibition mechanism Resistance mechanisms* 
Blasticidin S  PTC, termination DM, TM 
Chloramphenicol PTC DM, E, TA, TM 
Clindamycin, lincomycin PTC DM, E, TA, TM 
Dalfopristin (Streptogramin A)  PTC E, TA, TM 
Quinupristin (Streptogramin B) PTC E, TA, TM 
Erythromycin, telithromycin  Nascent chain elongation DM, E, TA, TM 
Evernimicin, avilamycin Initiation TA, TM 
Linezolid  PTC E, TA, TM 
Puromycin  PTC DM 
Sparsomycin PTC E, TM 
Thiostrepton   Factor binding TA, TM 
Tiamulin PTC E, TA, TM 
DM: drug modification/degradation; E: efflux/membrane permeability; PTC: peptidyl transferase center; TA: target 
alteration via modification (or lack thereof); TM: target mutation. *Typical resistance mechanisms (although others might 
exist). 
 
 
Resistance may be either inherent by the processes of genetic mutation or be acquired by 
gene transfer, through several genetic mechanisms, such as transformation, conjugation or 
transduction. This is termed horizontal evolution, and may occur between strains of the same 
species or different bacterial species or genera [4]. Although in some bacteria gene exchange occurs 
mainly by transformation, for many bacteria the most important vector of genetic exchange are 
plasmids, extra-chromosomal pieces of DNA. Plasmids are directly implicated in the acquisition of 
resistance to many antibiotics and their transmission is a key factor influencing plasmid-borne 
antibiotic resistance [12, 13].  
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Figure 1: Antibiotic binding sites on the 50S ribosomal subunit. (A) Overview of the binding sites of neomycin (Neo), 
evernimicin (Evn) and thiostrepton (Ths). The A-site tRNA (green), P-site tRNA (blue), E-site tRNA (orange), H43/H44, 
H69, peptidyl-transferase centre (PTC) and the L1 and L11 stalks are highlighted for reference. (B) Enlargement of the 
binding sites of blasticidin S (Bls1 and Bls2), sparsomycin (Spr), lincomycin (Lin), linezolid (Lnz), macrolides (Mac), 
puromycin (Pmn), pleuromutilins (Plu), chloramphenicol (Cam) and streptogramins A and B (SA and SB) relative to the 
A-site and P-site tRNAs [11].  
 
 
1.2. The cfr gene and the Cfr methyltransferase 
1.2.1. Identification of the plasmid-borne cfr gene 
The cfr gene was originally identified on a multi-resistance plasmid isolated from 
Staphyloccocus sciuri obtained from the nasal swab of a calf. Studies from the 90´s showed that 
antimicrobial resistance is common among this species, and some plasmids were identified as 
carriers of one or more resistance genes. This particular plasmid – pSCFS1 – carried the cfr gene, 
and was identified as a chloramphenicol-florfenicol resistance determinant and exhibited an 
unknown mechanism of resistance regarding both drugs, not only in its host but also in Escherichia 
coli [14]. To clarify how the gene was responsible for this resistance property, the inferred amino 
acid sequence of the Cfr protein was compared with other proteins known as responsible for 
resistance to the referred drugs, such as the multidrug efflux pumps family [15]. The results showed 
no homology to the efflux proteins and also to acetyltransferases, as well as the absence of 
characteristics of a transmembrane protein and the lack of ATP binding domains, which could help 
to predict the function of the protein [14, 16].   
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1.2.2. Cfr methyltransferase methylates at the PTC in the ribosome 
The mechanism of resistance towards chloramphenicol and florfenicol (phenicol) remained 
unknown. Thus, the possibility of Cfr affecting the drug target site was taken into account. 
Kehrenberg et al. investigated the binding of florfenicol, chloramphenicol and clindamycin to the 
ribosome to find out how Cfr was acting.  They observed that cells with Cfr showed a reduced 
binding of the drugs to the ribosome [17]. Chloramphenicol binds to the 50S ribosomal subunit, 
more specifically to the 23S ribosomal RNA domain in the peptidyl transferase centre. This drug 
protects sites in the highly conserved central loop of domain V and inhibits peptidyl transferase 
activity [18]. The search for a Cfr target confirmed that the mechanism of resistance was due to an 
altered ribosomal binding site. Kehrenberg et al. showed that Cfr was a methyltransferase that adds 
an extra methylation at position A2503. Besides, Cfr also caused a reduced ribose methylation at 
C2498 [17]. However, its specific identity and position remained to be clarified.  
 
1.2.3. Cfr methyltransferase belongs to the Radical SAM superfamily and methylates C-
8 at A2503 23S ribosomal RNA 
Database searches indicated that Cfr had some homology to a protein superfamily called 
Radical SAM (S-adenosylmethionine). Radical SAM proteins are associated with several ring-
forming reactions, pathways with sulphur transfer, anaerobic or oxygen-independent mechanisms, 
methylation reactions, isomerization and protein radical formation [19]. Proteins belonging to this 
family are related by the cysteine motif CxxxCxxC, which nucleates the [4Fe-4S] cluster, associated 
with generation of an oxidizing agent [20]. To corroborate that Cfr was a radical SAM protein, 
Giessing et al. performed some mutagenesis experiments in the cysteine motif CxxxCxxC, where 
each cysteine was replaced by alanine. E. coli strains expressing the mutated Cfr proteins showed 
that they were inactive, proving the essential role of the cysteine motif for Cfr activity and thus 
indicating a radical SAM methyltransferase mechanism [21].  
The same study, also, showed that the Cfr-mediated methylation at nucleotide A2503 of 
23S rRNA was in fact caused by methylation of the C-8. The m8A2503 modification is then 
responsible for the antibiotic resistance because of a steric interaction between the antibiotic and 
the methyl group added, that points into the drug-binding site [21]. In addition, this Cfr-mediated 
methylation was shown to be independent of the natural m2A2503 modification already reported 
in E. coli [22], and proved to be mediated by the RlmN methyltransferase in the ribosomes of Gram-
positive and Gram-negative bacteria [23]. Actually, the amino acid sequence of this RlmN 
methyltransferase also showed characteristics associated to the radical SAM superfamily [24]. 
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Therefore, the enzymes RlmN and Cfr methylate C-2 and C-8 of adenosine 2503, respectively, using 
SAM to methylate electrophilic rather than nucleophilic carbon centres. New mechanisms of 
methylation of A2503 were proposed for both RlmN and Cfr. It looks like Cfr evolved from RlmN 
and uses the same strategy to methylate C-8, but still have some capacity to also methylate C-2. 
The explanation is that Cfr has a less rigid substrate-binding pocket, allowing two different 
conformations, where a lysil residue acts as a general acid/base, while in RlmN this is a monoprotic 
residue [25]. Also, bioinformatics analysis of the Cfr/RlmN family suggested that it has a bacterial 
origin and also that RlmN had evolved in a vertical matter while Cfr evolved from horizontal 
transfer. RlmN may represent the ancestral form whereas cfr gene might have evolved from an 
rlmn gene, probably following duplications and horizontal gene transfer, but the lineage in which it 
happened was unidentified [26]. Despite their similarities, the methylation mediated by the RlmN 
methyltransferase is considered to be a housekeeping modification rather than a genuine antibiotic 
resistance determinant [21]; on the other hand, Cfr was proven to mediate resistance to various 
antibiotics, as explained below. 
 
1.2.4. Multiple resistance conferred by the Cfr methyltransferase  
Cfr methyltransferase was first confirmed as the responsible for three drugs resistance 
phenotype through methylation at position A2503, meaning resistance to phenicols 
(chloramphenicol and florfenicol) and lincosamide (clindamycin). If the Cfr affected the binding site 
of these drugs, probably other drugs that bind to the ribosomal peptidyl transferase centre could 
be affected too [27]. Pleuromutilins, oxazolidinones and streptogramin A antibiotics, all of clinical 
or veterinary importance, are known to bind close to A2503, becoming optimal candidates to 
susceptibility testing of strains carrying the cfr gene. Only some representatives of these antibiotic 
classes were used: tiamulin and valnemulin (pleuromutilin), linezolid (oxazolidinone) and 
virginiamycin M1 (streptogramin A). As observed for chloramphenicol, florfenicol and clindamycin, 
the presence of Cfr conferred resistance to these new drugs. Thus, we could expect that bacterial 
strains expressing Cfr would present decreased susceptibility to these five families of antibiotics. A 
new resistance phenotype was then established and named PhLOPSA for Phenicol, Lincosamide, 
Oxazolidinone, Pleuromutilin and Streptogramin A resistance, functioning in both Gram-positive 
and Gram-negative bacteria [27]. A later study showed that Cfr did not only provide resistance to 
these antimicrobial families but also decreased the susceptibility to 16-member-ring (large) 
macrolides (josamycin, spiramycin and tylosin), through the modification of A2503 [28].  
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These classes of antibiotics are known to bind close to A2503 in the 23S rRNA. Thus, it is important 
to determine ribosome-antibiotic interactions of each drug to understand how the modification 
caused by the Cfr protein can affect their binding. The structure model of the 50S subunit of 
Deinococcus radiodurans in complex with some antibiotics has been used as a reference to explain 
some of the ribosome-antibiotic interactions. Chloramphenicol (phenicol) is known to block 
peptidyl transferase activity by inhibiting the binding of tRNA to the A-site, showing several reactive 
groups that can form hydrogen bonds with various nucleotides of the peptidyl transferase cavity 
(Figure 2A). Clindamycin (lincosamide) interacts with the A- and P-sites, mainly through hydrogen 
bonds with the nucleotides of the 23S rRNA, and sterically blocks the progression of the nascent 
peptide towards the tunnel (Figure 2B) [29]. Schlünzen et al. showed the antimicrobial activity of 
the pleuromutilins at the molecular level, using tiamulin as a representative. Tiamulin was found to 
bind strongly in a cavity at the PTC, binding to the 23S rRNA through hydrophobic interactions 
involving exclusively nucleotides of domain V (Figure 2C) [30]. Streptogramins A act to prevent 
protein biosynthesis by interfering with substrate binding at the PTC, and thus blocking peptide 
bond formation. Dalfopristin, a representative of this class, is located in a tight pocket within the 
PTC, bound by several hydrophobic interactions as shown in Figure 2D [31]. Linezolid 
(oxazolidinone) binds in the A-site of the peptidyl transferase center of the ribosome and interacts 
with many 23S rRNA nucleotides in the neighborhood (Figure 2E) [32].  
If only one methyltransferase confers resistance to six classes of antimicrobial agents, then 
it is necessary to evaluate the cfr gene dissemination, to try to define how harmful it is and how to 
fight its spread. Otherwise many of these antibiotics of clinical importance will become useless. 
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Figure 2: Local environment of the antibiotic and its interaction with the peptidyl transferase cavity. Nucleotides 
interacting with (A) chloramphenicol (shown in green), (B) clindamycin (shown in green), (C) tiamulin (shown in 
orange), (D) dalfopristin (shown in orange) and (E) linezolid (shown in purple). Nucleotide numbering is according to 
the E. coli sequence [24-27]. 
 
1.2.5. Dissemination of the cfr gene  
The cfr gene only with minor sequence differences has been found on mobile genetic 
elements in different Staphylococcus isolates of animal and human origin, in different locations, 
such as Germany, Denmark and the United States [33-35]. In fact, the cfr gene has been found 
worldwide and in different organisms. In China, for example, the gene was detected in plasmids in 
Bacillus strains [36] and in the commensal bacteria Macrococcus caseolyticus and Jeotgalicoccus 
pinnipedialis [37], in novel plasmid types from five different species of staphylococci [38], in an 
Enterococcus faecalis isolate [39] and in three transferable plasmids obtained from other 
Enterococcus species [40]. Although in the beginning the gene was mainly found in animal sources, 
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it started to be frequently detected in clinical environments, in places like Italy [41, 42], Spain [43, 
44], Ireland [45] and Mexico [46], in many medical centres from the United States [47, 48], in 
Thailand [49] and in a clinical methicillin-resistant Staphylococcus aureus (MRSA) strain from 
Colombia, showing the capacity of the gene to disseminate among Gram-positive and other 
pathogenic strains [50]. Recently, another MRSA and a methicillin-resistant Staphylococcus 
haemolyticus strain were identified in a hospital in Spain [51]. Moreover, the cfr gene was also 
identified in naturally occurring Gram-negative bacteria: Proteus vulgaris [52] and Escherichia coli 
[53, 54].  
 These studies indicate how dispersed is the gene, which can be explained by the low fitness 
cost associated with gene acquisition and expression. LaMarre et al. investigated the fitness cost of 
cfr expression and they were able to conclude that acquisition of the cfr gene does not significantly 
reduce the cell growth rate. Thus, genes like cfr that come at a low cost can stably persist in the 
cells [55]. Furthermore, the cfr gene is found on plasmids or transposons (mobile genetic elements), 
allowing horizontal gene transfer. Also, the use of the already referred drugs can promote the 
maintenance of this gene in the population. All these findings demonstrate how worrying the cfr 
gene can be.  
 
1.2.6. Cfr-like proteins found in various bacteria 
 The cfr gene aroused the attention of many scientists. Given its dissemination worldwide, 
the next step was clearly to find similar genes encoding Cfr-like proteins and assess if they could 
confer resistance in a similar way as the Cfr methyltransferase. Through bioinformatics searches, a 
phylogenetic tree comprising predicted Cfr-like sequences was constructed. Three Cfr-like proteins 
from the order Bacillales (Bacillus amyloliquefaciens, Bacillus clausii and Brevibacillus brevis) were 
present [56], as well as genes from Enterococcus, Paenibacillus, and Clostridium, which led to the 
assumption that this group of Cfr-like proteins could contain real Cfr enzymes [57].  
The three genes from the order Bacillales were considered cfr-like because when expressed 
in E. coli they were able to decrease the susceptibility to the five classes of antibiotics in the PhLOPSA 
phenotype (florfenicol, clindamycin, linezolid, tiamulin, and streptogramin A/streptogramin B were 
used as representatives). Likewise, they verified the RNA methylation at A2503 in 23S rRNA by 
primer extension, to prove that the three Cfr-like proteins were acting through the same 
mechanism to confer the tested resistance [56]. Similarly, genes from Paenibacillus and Clostridium 
were cloned and expressed in E. coli. Induced expression was investigated by SDS gel analysis 
showing high levels of expression and MICs (minimum inhibitory concentrations) were determined 
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with five antibiotics from the PhLOPSA phenotype (florfenicol, clindamycin, linezolid, tiamulin and 
quinupristin-dalfopristin): ClPa (Cfr-like from Paenibacillus) conferred some resistance although 
less effective than the original Cfr methyltransferase (from S. sciuri); ClCs (Cfr-like from Clostridium) 
apparently did not mediate any changes in the MICs. The relationship between modification at 
A2503 in 23S rRNA and phenotype was also checked by primer extension. The results showed a 
clear stop at the position of interest in the RNA from ClPa (m8A2503 checked by mass spectrometric 
analysis), but no stop in the case of ClCs (in accordance with the MICs). The possible conclusion was 
that ClCs does not methylate 23S RNA from E. coli, but may be able to methylate Clostridium 23S 
RNA, due to sequence differences in the ribosome assembly process or in RNA and/or r-proteins 
[57]. These findings require further studies in order to try to establish if the cfr-like gene in 
Clostridium act as the Cfr methyltransferase and provide antibiotic resistance.  
 
1.3. Clostridium: the focus of the study  
Sequence alignments have shown that some Clostridium strains contain cfr-like genes, such 
as several C. botulinum and C. acidurici, C. sporogenes, C. phytofermentans and C. difficile [57]. The 
genus Clostridium includes diverse bacteria of medical and environmental importance, and mainly 
consists of Gram-positive, spore-forming, anaerobe rods, comprising toxin-producing species, such 
as C. botulinum and C. difficile, and also non-pathogens like C. sporogenes [58]. As several C. 
botulinum strains were suggested as cfr-like gene carriers, this species could represent an important 
subject of study regarding cfr-like genes. However, due to its pathogenic nature, working with C. 
botulinum requires Biosafety Levels for Laboratories – class 2 or 3 (BSL-2 and BSL-3) [59]. Thus, C. 
sporogenes, a similar species but non-pathogenic (in the sequence alignments mentioned above 
represented by two different strains), seemed to be the best species to work with.  
 
1.3.1. Clostridium sporogenes: the selected species 
 Phylogenetic analysis suggested that Clostridium sporogenes is closely related to C. 
botulinum, and thus it has been used as a non-toxigenic surrogate for proteolytic C. botulinum 
strains (because of the morphological similarities) in the derivation and validation of thermal 
processes in food [60, 61]. Two C. sporogenes strains were suggested as carriers of a cfr-like gene 
and the cfr-like gene of one of these strains was cloned and expressed in E. coli to investigate 
resistance to the PhLOPSA antibiotics [57]. As mentioned above, ClCs (Cfr-like from Clostridium) 
protein expressed in E. coli apparently did not mediate resistance to the tested antibiotics, which 
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calls for further studies. The obvious choice is thus to use C. sporogenes PA 3679 and C. sporogenes 
ATCC 15579 [57] to investigate how the Cfr-like protein function in Clostridium.   
 
1.4. Aim of the study   
Previous experiments of cloning and plasmid expression of the cfr-like gene from 
Clostridium sporogenes ATCC 15579 (clcs gene) in E. coli showed protein expression but no effect 
on antibiotic resistance and no modification of A2503 in ribosomal 23S RNA. In the first part of this 
study, the expression of the clcs gene in E. coli will be investigated by studying the strength of the 
induction of the gene as well as the effect of a lower constitutive expression of the gene by transfer 
it into another plasmid. The lack of function of the expressed protein will also be investigated by 
combining parts of the cfr gene with parts of the clcs gene to try to identify the differences and 
thereby determine why the Clostridium cfr-like gene does not function in E. coli. 
Furthermore, the question raised by Atkinson et al. [57] about the ability of the clcs gene 
to methylate its own host, the Clostridium 23S RNA, remained unanswered. So, the second part of 
the project will be the investigation of the function of the clcs gene in two Clostridium sporogenes 
strains to establish if the cfr-like genes in Clostridia act as Cfr and provide antibiotic resistance. 
Clostridium sporogenes will be obtained and established, as this is a new organism in the laboratory. 
Growth conditions for obtaining an exponential growing culture, procedures for RNA and DNA 
isolation will be developed. After RNA purification, primer extension will be performed to see if 
there is an indication of modification (a primer extension stop) at A2503 23S RNA. Moreover, a 
fragment around A2503 has to be isolated and investigated by mass spectrometry to determine 
whether the strain has m8A2503 methylation in its 23S ribosomal RNA. The antibiotic resistance 
pattern of the Clostridium sporogenes strains will also be investigated. 
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2. Results and Discussion 
2.1. Part I – Cloning of cfr and cfr-like genes in E. coli 
2.1.1. Preliminary analysis of growth after induction of cfr-like genes 
In 2012, Hansen et al. identified three cfr-like genes from the order Bacillales. These genes 
were cloned into plasmids under the control of an inducible promoter and transformed into E. coli 
AS19 [62]. The expression of the cfr-like genes was induced and SDS gel analysis showed expression 
of the Cfr-like proteins [56]. However, a previous study performed in the “BV lab” indicated poor 
growth after induction of the clcs gene – a cfr-like gene from Clostridium sporogenes [57]. The 
apparent growth inhibition of E. coli caused by expression of the clcs gene was therefore 
investigated in the beginning of this study. Growth curves with induced plasmids were performed 
and E. coli AS19 cells expressing pClCs (a derivative of the plasmid pLJ102 carrying the clcs gene) 
seemed to be impaired following the induction of the ClCs protein with 1mM IPTG, the amount 
shown to be needed for the expression of the protein. Simultaneously, the growth of cells that were 
not induced with IPTG or induced with less IPTG (0.2 mM) was not affected (Figure 3). 
 
 
Figure 3: The green line shows the growth of E. coli AS19/pClCs cells that have not been induced with IPTG. The blue 
and yellow lines show the growth of cells that have been induced with 1 mM IPTG and 0.2 mM IPTG, respectively, and 
thus, express ClCs.   
 
Based on the growth curves made, a clear difference in growth was observed between cells 
that carry pClCs and have been induced with 1mM IPTG compared to those that have not been 
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induced with IPTG (and hence, do not express the protein) or with 0.2mM IPTG. These growth 
curves indicated that the expression of the ClCs protein somehow impairs the growth of these cells.  
Since the strength of the clcs gene induction was investigated and the inducible plasmid 
seemed to hamper the study of the protein function, clcs gene was transferred into another 
plasmid. The new plasmid should then allow a constitutive expression of the gene, avoiding the 
need of induction. Thus, the vector chosen was pBR322 [63]. Three new constructs were made to 
obtain plasmids expressing constitutively the clcs, cfr and scfr genes: the plasmid pCfrHisN [21], 
containing the wild-type cfr gene cloned into the NdeI and HindIII sites of plasmid pLJ102 [64] was 
provided by “BV group”; the synthetic scfr and clcs genes were designed to be codon optimized for 
E. coli. The scfr gene was designed to contain AvrII and XhoI restriction sites, and clcs gene to 
contain HindIII and NdeI restriction sites at the ends, but it was already cloned into the plasmid 
pLJ102 for previous experiment in the “BV lab”. The genes were inserted into plasmid pBR322 
replacing the tet gene. The vector part of pBR322 with the amp gene was constructed by PCR to 
contain AvrII-CCTAGG and XhoI-CTCGAG restriction sites near the ends. The clcs and cfr genes were 
also amplified by PCR and were constructed to contain AvrII-CCTAGG and XhoI-CTCGAG restriction 
sites (the same sites as the vector) near the ends. The scfr gene already contained AvrII and XhoI 
restriction sites at its ends. The new plasmids were named pBRClCs, pBRCfr and pBRsCfr, 
respectively.  
New growth curves were performed using E. coli AS19 cells expressing pBRClCs, pBRCfr and 
pBRsCfr. Figure 4 shows that the growth of the tested strains was not inhibited. As presented in the 
figure, E. coli AS19 cells harbouring the plasmid pBR322 grew at the same rate as E. coli AS19 cells 
without plasmid, meaning that carrying the plasmid has no effect on E. coli AS19 growth. Similarly, 
the cells harbouring the plasmids that carry the genes of interest, pBRsCfr and pBRClCs, are growing 
equally fast. Considering this result, changing the plasmid to obtain a constitutive expression of the 
genes was considered the best solution to obtain a growth similar to the wild-type E. coli AS19. 
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Figure 4: The blue line shows the growth of E. coli AS19 cells with no plasmid. The orange, grey and yellow lines follow 
the growth of E. coli AS19 cells harboring the plasmids pBR322, pBRsCfr and pBRClCs, respectively.   
 
2.1.1. Antibiotic susceptibilities of the strains expressing Cfr and Cfr-like proteins 
Recent studies demonstrated the antibiotic susceptibilities of strains expressing the wild-
type Cfr and Cfr-like proteins, namely the three Cfr-like proteins from the order Bacillales and the 
ClCs from Clostridium sporogenes [56, 57]. However, the genes encoding for these proteins were 
cloned into an inducible plasmid. Since the genes encoding for sCfr and ClCs proteins were cloned 
into pBR322, it was necessary to perform a Minimum Inhibitory Concentration (MIC) analysis to 
evaluate whether the inserted cfr and cfr-like genes confer changes in the antibiotic susceptibility 
and to establish if the Cfr-like protein ClCs confers a resistance pattern similar to that of the Cfr 
methyltransferase. Thus, the MICs were conducted including controls with Cfr-positive and Cfr-
negative E. coli AS19 [62], a hyperpermeable strain used to emphasize the observed effects because 
it is much more sensitive to antibiotics than other E. coli strains that have a relatively low 
susceptibility to many drugs. 
 The strains E. coli AS19/pBRCfr, AS19/pBRsCfr and AS19/pBRClCs together with the control 
strains without plasmid, the parent pBR322 plasmid and the pBglII plasmid that constitutively 
expresses Cfr [17] were exposed to three antibiotics at various concentrations: tiamulin, 
chloramphenicol and linezolid. These antibiotics represent three out of the five antibiotic classes in 
the PhLOPSA phenotype conferred by the Cfr methyltransferase and thus represent a good initial 
indicator of the phenotype [27]. The minimum inhibitory concentration for each strain was defined 
as the drug concentration at which the growth of the cultures was completely inhibited after 24 h 
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of incubation at 37°C. The ODs of the growth in media plus 20% were used as cut-off value. The MIC 
results are shown in Table 2.  
 
Table 2: Comparison of antimicrobial susceptibilities to 3 antibiotics in the presence or absence of the Cfr or Cfr-like 
methyltransferases in E. coli AS19.  
E. coli AS19 
strain/plasmid 
cfr/cfr-like gene 
MIC (μg/mL) 
Tiamulin Chloramphenicol Linezolid 
none - 1 1 8 
pBRCfr + 4 2 16 
pBRsCfr + >32 8 >64 
pBRClCs + 1 1 8 
pBR322 - 1 1 8 
pBglII + 32 4 32 
pBRsCAC + 2 2 --- 
pBRCAsC + 2 1 --- 
 
As expected, sCfr confered resistance to the tested antibiotics being as effective as the 
positive control pBglII and lowering the sensitivity to all three antibiotics. In contrast, Cfr showed 
lower effectiveness than sCfr, probably because it is not codon optimized for E. coli, which resulted 
in a minor protein expression. As far as ClCs is concerned, it does not mediate MIC changes (MICs 
comparable to the negative controls). According to the results published by Atkinson et al. [57], 
where the inducible plasmid pLJ102 was used to clone cfr and clcs genes, the effect of the sCfr and 
ClCs proteins on tiamulin and linezolid MICs is similar to the effect observed here for the same 
antibiotics. Hence, the constitutive expression of the proteins did not change its effect in E. coli 
AS19 cells and the results obtained are reliable, showing once again the inability of ClCs to confer 
resistance.     
CICs is not fully characterized yet and few information about its function and amino acids 
sequence is available. Therefore, the lack of function of the expressed protein was also investigated 
by combining parts of the scfr and clcs genes to try to identify any differences. The genes scfr and 
clcs have a common restriction site ( A CRYG T), also present in the vector pBR322. Hence, starting 
from the plasmids pBRsCfr and pBRClCs cut with the double cutter restriction enzyme AflIII (Figure 
5), two other plasmids were obtained: pBRsCfrAflIIIClCs (initial part of scfr and final part of clcs) and 
pBRClCsAflIIIsCfr (initial part of clcs and final part of scfr). They were named pBRsCAC and pBRCAsC, 
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respectively (Figure 6). E. coli AS19 strains harboring these constructs were only tested with 
tiamulin and chloramphenicol and the MIC results (Table 2) showed no ability of the sCAC and CAsC 
to lower the susceptibility of the cells, as already observed for the ClCs and negative controls. The 
combination of parts of scfr and clcs genes was an attempt to understand the lack of function of 
the ClCs and to try to define if parts of ClCs could be functioning as the corresponding areas of Cfr 
or to define which part prevents the function. However, the results did not allow us to reach a 
conclusion other than the combinations made did not produce a cfr-like effect and did not reduce 
the antibiotic susceptibility. Thus, further studies are needed where more combinations should be 
tried. 
 
Figure 5: Plasmids pBRClCs and pBRsCfr showing the restriction sites where AflIII cuts producing two fragments in each 
plasmid. 
 
 
Figure 6: Plasmids constructed from pBRClCs and pBRsCfr. pBRsCfrAflIIIClCs (pBRsCAC) contains the first part of scfr 
and second part of clcs, and pBRClCsAflIIIsCfr (pBRCAsC) comprises the first part of clcs and second part of scfr. 
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2.1.2. Verification of cfr and cfr-like genes expression by SDS gel analysis and protein 
identification by mass spectrometry 
As mentioned above, the cfr and cfr-like genes were cloned into an inducible plasmid and 
the expression of these genes was induced by addition of IPTG and then investigated by SDS gel 
analysis of total protein from the used strains.  The MICs revealed how Cfr and ClCs proteins 
affected the cells expressing them, but the expression level of Cfr and Cfr-like proteins in the 
expression system used (proteins are constitutively expressed and does not require induction) also 
had to be investigated. 
As shown in Figure 7, no protein bands were detected with the expression of sCfr and ClCs 
at the expected masses (sCfr, 39.86 kDa and ClCs 39.18 kDa). Based on the MIC results, expression 
of sCfr and positive control was expected, or at least visible differences in the bands’ intensities. 
The plasmid pBglII expresses the Cfr constitutively and was used both in previous studies and this 
study, so similar results were expected. Hansen et al. [56] could not correlate quantitatively the 
expression level of each protein and the MIC effects, but a good expression of the Cfr-like proteins 
was always observed. As far as ClCs is concerned, strong protein band appeared with its expression 
[57]. The SDS gel analysis did not show the expression of the proteins, which was not expected 
taking into account the MIC results and previous results with the same positive control, pBglII. 
 
 
 
 
 
~39 kDa 
Figure 7: Analysis of cell extracts by SDS-PAGE, to verify expression of Cfr and Cfr-like proteins. The cell 
extracts are from E. coli AS19 cells alone and harboring the plasmids pBglII, pBRClCs, pBRCfr and pBRsCfr, as 
indicated above the gel. The marker indicates size markers at 130, 100, 70, 55, 35 and 25 kDa (from the top). 
The red box indicates the presumable expression of Cfr or Cfr-like proteins. 
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In order to detect the non-visible proteins, protein identification by mass spectrometry was 
performed. A thicker and bigger SDS gel was prepared to obtain higher amounts of the proteins and 
the presumed bands were cut to be investigated by mass spectrometry (Figure 8). The analysis 
revealed that all samples, including the negative control, had the same protein, which was in fact a 
Glyceraldehyde-3-phosphate dehydrogenase with a mass of almost 36 kDa (Figure 9).  In the 
“normal” SDS gel, the assumed correct bands were slightly above the 35 kDa, corresponding to the 
area of the ~39 kDa. Some differences in the intensity were detected but they were not significant 
enough to reach a conclusion. However, the mentioned region was identified as the region of 
interest. Comparisons were made between the “normal” and the “adapted” gels, bands and blank 
spaces were analyzed. The region showed in Figure 8 was considered the corresponding one to the 
previously identified in the “normal” gel. The bands in this region were cut, digested with proteases 
and further analysed in the mass spectrometer. Results indicated that the analyzed bands were not 
the correct ones. Given the results, protein expression should be further analyzed because there is 
no visible reason or cause for inhibition or no expression. One possible direction would be 
performing a Western Blot analysis of the Cfr and Cfr-like proteins since it allows the detection of a 
specific protein. Though, this technique requires primary antibodies against the protein of interest, 
which are not available since the protein was never purified. Some companies can design the 
intended antibody but the process is not cheap and is time consuming. 
 
 
 
 
 
 
 
 
Figure 8: SDS gel to obtain higher amounts of the proteins for 
further mass spectrometry analysis. The same E. coli AS19 cell 
extracts were used as in the “normal” SDS gel (except pBglII). 
The marker indicated in the picture as M, indicates size 
markers at 250, 130, 100, 70, 55, 35 and 25 kDa (from the top). 
The arrows indicate the bands cut to be analyzed by mass 
spectrometry.  
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Figure 9: Resulting spectra from protein 
mass spectrometry of the bands excised 
from the SDS gel. The spectra show that 
all bands contain the same proteins.  
 
2.1.3. Primer extension analysis to verify modification at A2503 23S rRNA   
Although the lack of resistance to the three antibiotics is an indicator that ClCs and the 
combined proteins sCAC and CAsC are not acting as the Cfr methyltransferase, the verification of 
the presence or absence of the RNA methylation at A2503 in 23S rRNA was checked by primer 
extension. The plasmids pBRCfr, pBRsCfr, pBRClCs, pBglII, pBRsCAC and pBRCAsC were transformed 
into the ΔRlmN strain E. coli JW2501-1 [65] once it facilitates identification of Cfr methylation by 
avoiding interference from the RlmN m2A2503 methylation. Total RNA was purified and subjected 
to primer extension by reverse transcriptase. A fluorescently labeled oligonucleotide (Cy5-labeled, 
5’–GAACAGCCATACCCTTG–3’) was annealed to the desired region (nucleotides 2540 to 2556 of E. 
coli 23S ribossomal RNA) and extended until stopped by structures in RNA or modifications, or by 
breakage of RNA caused by enzymatic degradation or simple water hydrolysis. An RNA modification 
that interferes with base pairing will stop or pause reverse transcriptase one nucleotide before the 
modified base, which is expected to occur in case of methylation of the position A2503. The 
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resulting cDNA extension products were separated on 6% polyacrylamide sequencing gel alongside 
dideoxy sequencing reactions. 
The analysis is presented in Figure 10A and shows a clear stop at A2503 of 23S RNA from 
sCfr (Cfr from pBglII also mediates a strong stop), and a weaker stop in the case of Cfr. These 
observations are consistent with the resistance observed in the MIC experiment. As expected, the 
negative control E. coli JW2501-1 does not give rise to any stop at the A2503 position. There is also 
no stop in the ClCs-containing strain, consistent with no observed MIC changes, revealing that Cfr-
like from Clostridium sporogenes does not methylate E. coli 23S RNA. Figure 10A also shows a 
reverse transcriptase stop at position C2498, caused by the 2’-O-ribose methylation [17]. This stop 
is decreased in the case of pBRsCfr and pBglII, meaning that sCfr and Cfr from pBglII reduce the 
amount of Cm2498 in ribosomes as reported [17]. On the other hand, pBRClCs does not affect the 
stop at this position. ClCs does not modify A2503 and consequently does not affect the nucleotide 
C2498. Figure 10B shows the primer extension of the plasmids carrying the combined genes, psCAC 
and pCAsC. Due to the acquisition of a new device (fluorescence scan) used for the visualization of 
the gels, the picture obtained does not allow the reading of the sequence. However, some of the 
plasmids showed in Figure 10A are also present in Figure 10B, allowing the comparison. Thus, it is 
possible to recognize the stops at A2503 mediated by sCfr and Cfr from pBglII, and no stops in the 
same region are observed in the case of the combined proteins.  
It is not possible to conclude that ClCs does not have a Cfr-like function. All in all, this protein 
may be able to methylate Clostridium 23S RNA but not E. coli 23S RNA, because of some differences 
in RNA sequence or r-proteins, or in the ribosome assembly process. Further studies are needed to 
investigate if ClCs play a similar role in its natural host.      
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Figure 10: Primer extension analysis made on a 6% acrylamide gel with urea. The picture presented here is limited to 
the nucleotides flanking A2503 and shows the stops on 23S rRNA from E. coli JW2501-1 strain alone and harboring the 
plasmids (A) pBRCfr, pBRsCfr, pBRClCs and pBglII and (B) pBRsCAC, pBRCAsC, pBRsCfr and pBglII.  The first four lanes 
in (A) and last four in (B) (C, U, A and G) correspond to the sequencing reactions. The nucleotides of interest (C2498 
and A2503) are pointed by the arrows (one position below the sequencing position, once the extension stops before 
the modified nucleotide).  
 
2.2. Part II – Investigation of the function of the Clostridium cfr-like 
gene in C. sporogenes PA 3679 and C. sporogenes ATCC 15579 
The cloning and expression of the cfr-like gene from Clostridium sporogenes (clcs) in E. coli 
showed that the ClCs protein does not confer resistance to the PhLOPSA antibiotics tested and does 
not methylate the position A2503 in E. coli 23S rRNA. Thus, the main purpose of the second part of 
the study was to establish if the cfr-like gene in Clostridium could act as Cfr and provide antibiotic 
resistance and also verify whether the strains C. sporogenes PA 3679 and C. sporogenes ATCC 15579 
had a methylation at A2503 in their 23S ribosomal RNA. 
 
                                           A                                                                                           B 
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2.2.1. Confirmation of the identity of the strains  
Clostridium sporogenes PA 3679 and C. sporogenes ATCC 15579 were newly obtained 
strains in the laboratory and no previous knowledge about their growth conditions was available, 
which required some prior preparation. The strains were then grown at 37°C ([66], [67] and ATCC 
recommendation) and due to the anaerobic atmosphere required for the growth of these 
Clostridium strains, Hungate-tubes [68] were used since they allow the removal of the oxygen 
present in the broth, by the addition of nitrogen, in order to obtain an anaerobic gas mixture of 
approximately 80% N2, 10% O2 and 10% H2, as recommended by the suppliers of the strains. To 
incubate the strains after plating, an anaerobic jar with a sachet of Anaerocult A or AnaeroGen was 
used. These sachets contain components, which chemically bind oxygen quickly and completely, 
creating an oxygen-free (anaerobic) environment – Figure11.  
To verify the identity of the strains, PCR reactions were performed to amplify the 16S 
ribosomal RNA (Table 3) and then the PCR products were sequenced and analysed using nucleotide 
blast (http://blast.ncbi.nlm.nih.gov/) in order to determine the genus of the strains. In both 
situations the identity of the strain was confirmed. 
 
 
 
2.2.2. Amplification and sequencing of the cfr-like gene  
Likewise, the cfr-like gene had to be amplified, sequenced and analysed as done for the 16S 
rRNA.  We first started with C. sporogenes PA 3679, and many trials were made in order to amplify 
the cfr-like gene, as shown in Table 3. Also, gradient PCR with some of the primers was performed 
in an attempt to find the proper annealing temperature, if that was the cause of the negative 
results. Still, no gene presence could be detected. Thus, some combinations of the primers were 
made such as BV472 (forward) and BV471 (reverse), BV470 (forward) and BV473 (reverse), BV477 
                                           A                                                           B                                                             C 
Figure 11: (A) Hungate-tubes used to maintain the anaerobic conditions. (B) Addition of nitrogen gas into the Hungate-
tubes causes oxygen removal. (C) Anaerobic jars used to incubate the strains after plating. 
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(forward) and BV471 (reverse), and BV470 (forward) and BV478 (reverse), but again it was not 
possible to amplify the gene.  
 
Table 3: Primers and PCR conditions used to isolate 16S rRNA and cfr-like gene from Clostridium sporogenes PA 3679 
and C. sporogenes ATCC 15579. Note: The annealing temperature for the primers was calculated using NEB 
Calculator, according to the manufacturer’s instructions. 
  Primers (5’ → 3’) PCR conditions 
B
o
th
 s
tr
ai
n
s 
16S rRNA 
BV468 (forward) 
GTGAAATGCGTAGAGATTAGGAA 
BV469 (reverse) 
GATTCGCGATTACTAGCAACTC 
Initial denaturation (98°C): 1  min; 30 cycles, 
denaturation (98°C): 10 sec, annealing (64°C): 30 
sec, extension (72°C): 20 sec and final extension 
(72°C): 10 min 
C
. s
p
o
ro
g
en
es
 P
A
 3
6
7
9 
cfr-like gene 
(primers 
flanking the 
gene) 
BV470 (forward) 
AGGTTCGAGCAAAGGCTATTTCA 
BV471 (reverse) 
GATGTTTTGGGCGACGCTTG 
Initial denaturation (98°C): 1  min; 30 cycles, 
denaturation (98°C): 10 sec, annealing (67°C): 30 
sec, extension (72°C): 38 sec and final extension 
(72°C): 10 min 
cfr-like gene 
(primers 
flanking the 
gene) 
BV472 (forward) 
GTAGCCCATTATGCTCCCTCC 
BV473 (reverse) 
CAATAGGCTCCATGCAAAGCC 
Initial denaturation (98°C): 1  min; 30 cycles, 
denaturation (98°C): 10 sec, annealing (69°C): 30 
sec, extension (72°C): 36 sec and final extension 
(72°C): 10 min 
cfr-like gene 
(primers 
flanking the 
gene) 
BV477 (forward) 
TACTCCACGTTGAGCACACA 
BV478 (reverse) 
CTTTCCAGCTCGGCAAAACG 
Initial denaturation (98°C): 1  min; 30 cycles, 
denaturation (98°C): 10 sec, annealing (63°C): 30 
sec, extension (72°C): 72 sec and final extension 
(72°C): 10 min 
cfr-like gene 
(primers within 
the gene) 
BV480 (forward) 
CCGGATTTGCAAAAGCCTCA 
BV481 (reverse) 
AAACAGGGGTGGGAATCGTT 
Initial denaturation (98°C): 30 sec; 30 cycles, 
denaturation (98°C): 10 sec, annealing (67°C): 30 
sec, extension (72°C): 10 sec and final extension 
(72°C): 2 min 
Upstream cfr-
like gene (gene 
encoding ATP-
binding protein) 
BV479 (forward) 
TCACAAAATGCACTATCATGCTCAA 
BV478 (reverse) 
CTTTCCAGCTCGGCAAAACG 
Initial denaturation (98°C): 30 sec; 30 cycles, 
denaturation (98°C): 10 sec, annealing (66°C): 30 
sec, extension (72°C): 23 sec and final extension 
(72°C): 2 min 
Downstream 
cfr-like gene 
BV482 (forward) 
GGACTACGCTATGCTCGGTT 
BV471 (reverse) 
GATGTTTTGGGCGACGCTTG 
Initial denaturation (98°C): 30 sec; 30 cycles, 
denaturation (98°C): 10 sec, annealing (68°C): 30 
sec, extension (72°C): 84 sec and final extension 
(72°C): 2 min 
C
. s
p
o
ro
g
en
es
 
A
TC
C
 1
5
5
7
9
 cfr-like gene 
(primers 
flanking the 
gene) 
BV473 (forward) 
CAATAGGCTCCATGCAAAGCC 
BV472 (reverse) 
GTAGCCCATTATGCTCCCTCC 
Initial denaturation (98°C): 30 sec; 30 cycles, 
denaturation (98°C): 10 sec, annealing (68°C): 30 
sec, extension (72°C): 52 sec and final extension 
(72°C): 2 min 
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At this point, it is required to refer that the C. sporogenes PA 3679 sequence is in the 
databases but divided in more than a hundred contigs, and the cfr-like gene belongs to one small 
contig, together with two other genes (one gene encoding for an ATP-binding protein and other 
encoding for a hypothetical protein) – Figure 12. The division of the sequence in so many parts may 
be more likely to contain mistakes, as well as the impossibility to amplify the gene may indicate 
some problem with the contig containing the cfr-like gene, or even that the presence of a cfr-like 
gene may not be as certain as primarily assumed. Thus, two pairs of primers were designed to 
isolate the genes upstream and downstream the cfr-like gene (both genes are in the same contig). 
Once again, it was not possible to amplify any of the genes. Given the absence of results, DNA 
degradation was considered to be the problem. A new kit for DNA extraction “DNeasy and Blood 
Tissue Kit (Quiagen) – Pretreatment for Gram Positive Bacteria” was then obtained. However, 
despite no degraded DNA, the amplification of the genes was still not possible. As a last try, a new 
pair of primers complementary to an essential gene (DNA polymerase III) placed in a different contig 
of the cfr-like gene was designed. This PCR amplified the desired gene showing that the 
chromosomal DNA was in good condition. A possible explanation is the absence of the cfr-like gene 
in the genomic DNA and maybe it could be placed on a plasmid. So, we tried to isolate potential 
plasmids and amplify the gene, but no PCR products were obtained. The only likely conclusion was 
the absence of the cfr-like gene in C. sporogenes PA 3679, unlike what the databases suggest. We 
decided to obtain another strain, C. sporogenes ATCC 15579. A PCR reaction was performed and 
the cfr-like gene was amplified, immediately. Notice that the sequence of this strain is in the 
databases divided in just three scaffolds and hence, probably less likely to contain mistakes.   
The assumption of these two C. sporogenes strains to contain a cfr-like gene [57], seemed 
to be true for only one of them. Thus, it was possible to try to establish if the cfr-like gene in C. 
sporogenes ATCC 15579 could act as Cfr and provide antibiotic resistance, and also compare the 
ATCC 15579 with the presumably Cfr-lacking strain C. sporogenes PA 3679. 
 
Figure 12: Picture adapted from the information system PATRIC (Bacterial Bioinformatics Resource Center), 
showing the Cfr-like protein and the two other proteins upstream (ATP-binding protein) and downstream 
(hypothetical protein) present in the same contig. The arrows and numbers indicate the nucleotides, showing how 
the proteins are positioned relative to each other.  
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2.2.3. Antibiotic susceptibilities of the Clostridium sporogenes strains 
Little information about antibiotic susceptibilities of C. sporogenes strains can be found in 
the literature. However, it is relevant for the study to investigate if the cfr-like gene in C. sporogenes 
ATCC 15579 can act as Cfr and provide antibiotic resistance, and compare the results with the 
presumably Cfr-lacking strain C. sporogenes PA 3679. MICs were conducted to assess if the Cfr-like 
protein found in C. sporogenes ATCC 15579 could confer a resistance pattern similar to that of the 
Cfr methyltransferase. In this experiment, C. sporogenes PA 3679 could be used as a negative 
control, assuming that it does not have the cfr-like gene.  
Both strains were exposed to nine antibiotics, at various concentrations. Tiamulin and 
valnemulin (pleuromutilin), chloramphenicol (phenicol), linezolid (oxazolidinone), clindamycin 
(lincosamide) and synercid (streptogramin) represent the five antibiotic classes in the PhLOPSA 
phenotype conferred by the Cfr methyltransferase, which means that those are drugs binding to 
overlapping sites at the peptidyl transferase center. To verify if any of the strains could provide 
natural resistance or lower susceptibility to the PhLOPSA antibiotics, and thus invalidate the results 
obtained, three other antibiotics were tested: erythromycin, a small macrolide (since Cfr confers 
resistance to large macrolides) and kanamycin and streptomycin, both aminoglycosides that 
perturb peptide elongation at the 30S ribosomal subunit. The minimum inhibitory concentration 
for each strain was defined as the drug concentration at which the growth of the cultures was 
completely inhibited after 24 h of incubation at 37°C.  The MIC results are shown in Table 4.  
 
Table 4: Comparison of antimicrobial susceptibilities of both C. sporogenes strains to 9 antibiotics, six representatives 
of the PhLOPSA phenotype, one macrolide and two aminoglycosides. 
MIC (μg/mL) C. sporogenes PA 3679 C. sporogenes ATCC 15579 
Tiamulin  8-16 128 - >128 
Valnemulin  --- 32 
Chloramphenicol  0.25 1 
Linezolid  0.25 0.5 
Clindamycin  <0.125 1-2 
Synercid  <0.125 0.5 
Erythromycin  0.5 0.5 
Kanamycin  8 - >8 4 
Streptomycin  8 - >8 8 - >8 
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Analyzing the MICs and comparing the results obtained from both strains, C. sporogenes 
ATCC 15579 showed lower susceptibility to all the PhLOPSA antibiotics tested than C. sporogenes 
PA 3679. As far as the aminoglycosides and the small macrolide are concerned, both strains showed 
similar MICs, which may indicate that none of the strains is naturally more resistant than the other. 
A study from the 80’s [69] showed the antibiotic susceptibilities of six C. sporogenes strains isolated 
from animals. When all the six strains showed resistance to an agent, they were considered 
naturally resistant to the agent. It was seen for tiamulin (pleuromutilin), clindamycin and lincomycin 
(lincosamides), and virginiamycin component M (streptogramin A), which are three of the PhLOPSA 
antibiotic classes tested in our study. Thus, we can suggest that C. sporogenes PA 3679 is not a real 
C. sporogenes strain and therefore does not show similar MICs for tiamulin and clindamycin as C. 
sporogenes ATCC 15579, or that Cfr-like protein may confer some resistance to C. sporogenes ATCC 
15579, or another mechanism in this strain is responsible for the resistance observed. Since the 
function of the Cfr-like protein is uncertain and no further information regarding resistance to 
antibiotics is available in the literature, the most suitable approach was to investigate if the Cfr-like 
protein was acting as the Cfr methyltransferase and methylates the A2503 in the 23S rRNA from C. 
sporogenes ATCC 15579.  
 
2.2.4. Primer extension analysis to verify modification at A2503 23S rRNA from C. 
sporogenes strains (E. coli numbering) 
The possible resistance conferred by the Cfr-like protein from C. sporogenes ATCC 15579, 
the uncertainty about its function, and the presumable absence of the cfr-like gene in C. sporogenes 
PA 3679, led us to the necessity to verify by primer extension if there was an indication of 
modification (a primer extension stop) at A2503 23S rRNA from C. sporogenes (E. coli numbering) 
as the one caused by Cfr methyltransferase and other Cfr-like proteins in E. coli.  
Fresh cultures of both strains were growing for around 6.5 hours to allow new ribosomal 
RNA to be transcribed, modified, and incorporated into ribosomes. Then, the total RNA was purified 
and a 5’-[32P]-labeled deoxyoligonucleotide (5’– GAACAGCCCAACCCTTG–3’) was annealed to the 
nucleotides 2540 to 2556 of C. sporogenes 23S ribosomal RNA (E. coli numbering). The reaction was 
extended until stopped by modifications or secondary structures as explained in part I. The resulting 
cDNA extension products were separated on 6% polyacrylamide sequencing gel alongside dideoxy 
sequencing reactions. 
The analysis is presented in Figure 13 in two different gels, since the gel that comprises both 
strains is missing a lane (U). Thus, the gel with only C. sporogenes PA 3679 is used to compare the 
  Investigation of a cfr-like gene from Clostridium 
26 
 
sequence reading. Figure 13 shows a visible but not too strong stop at A2503 of 23S rRNA from 
either C. sporogenes strains. In the case of C. sporogenes PA 3679 (Figure 13A), a strong stop was 
not expected due to the absence of the cfr-like gene. However, C. sporogenes ATCC 15579 was 
expected to mediate a strong stop, if its Cfr-like protein was acting as Cfr in E. coli. In both cases 
(Figure 13B), a slight band is visible, which can be explained due to the presence of an rlmN-gene 
in both strains. To verify the conclusion, mass spectrometry was performed to identify any 
modification around A2503 23S ribosomal RNA in the strains C. sporogenes PA 3679 and C. 
sporogenes ATCC 15579.  
 
 
Figure 13: Primer extension analysis made on a 6% acrylamide gel with urea. The picture presented here is limited to 
the nucleotides flanking A2503 and shows the stops on 23S rRNA from both Clostridium sporogenes ATCC 15579 and 
PA 3679 (E. coli numbering). (A) C. sporogenes PA 3679 and (B) C. sporogenes ATCC 15579 and C. sporogenes PA 3679. 
The first four lanes (C, U, A and G) correspond to the sequencing reactions. The nucleotide of interest A2503 are pointed 
by the arrows (reverse transcriptase stops one nucleotide before the modified nucleotide in the sequencing lanes). 
 
2.2.1. MALDI-TOF analysis of a defined rRNA sequence around A2503 
To investigate the inconclusive effects observed on the primer extension gels and further 
define any modification, a matrix-assisted laser desorption ionization – time of flight (MALDI-TOF) 
                                               A                                                   B 
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mass spectrometry (MS) analysis was performed. MALDI has been demonstrated as an alternative 
method to analyse RNA modifications [70]. This technique is generally advantageous in terms of 
sensitivity and the final result is the generation of singly charged molecular ions, which reduce the 
complexity of the spectrum [71]. The MALDI technique in this study was used to detect and localize 
a predicted but unknown modification (A2503) in domain V central loop of 23S rRNA from C. 
sporogenes. 
A fragment composed by 48 nucleotides as seen in Figure 14 around A2503 (5’–
GCCCCAGGATGCGACGAGCCGACATCGAGGTGCCAAACCTCCCCGTCG–3’), comprising positions 
2480-2527 of 23S rRNA from C. sporogenes (E. coli numbering) was isolated and investigated by 
mass spectrometry to determine if the modification was m2A (from RlmN methyltransferase) or 
m8A (from Cfr-like enzyme methyltransferase) or maybe both. After fragment purification, the RNA 
was digested with the G-specific RNase T1, which gives small characteristic fragments suitable for 
detailed analysis. RNase T1 cleaves after guanosine at the 3’ –end through a 2’ -, 3’ –cyclic 
phosphate intermediate reaction [70]. The theoretical masses of the generated fragments from the 
gene sequence of the rRNA fragment isolated were calculated using GPMAW (Table 5). 
 
 
 
 
 
 
 
 
 
Figure 14: Secondary structure of domain 
V central loop of 23S rRNA from C. 
sporogenes, adapted from E. coli 23S rRNA 
secondary structure. The region in grey 
corresponds to E. coli, thus shouldn’t be 
taken into account. The black line limits 
the fragment isolated and investigated by 
mass spectrometry. The red A corresponds 
to the adenosine in position 2503 (E. coli 
numbering).    
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Table 5: Theoretical calculated masses of the 48nt fragment around A2503 from C. sporogenes after RNase T1 
digestion. *Dinucleotides were not considered. 
Mass (linear) Position Fragment 
669.11 2480 – 2481 CG* 
693.12 2488 – 2489 AG* 
975.13 2506 – 2508 UCG 
975.13 2514 – 2516 UCG 
998.16 2482 – 2484 ACG 
999.14 2503 – 2505 AUG 
1280.17 2510 – 2513 CUCG 
1282.14 2491 – 2494 UUUG 
2219.31 2496 – 2502 CACCUCG 
2220.29 2517 – 2523 CAUCCUG 
 
The obtained signals were compared to the theoretical values listed above. Mono- and 
dinucleotides were not considered because their mass region is dominated by signals from the 
matrix or buffers in the MALDI-TOF mass spectra. Figure 15 shows the general spectrum and the 
relevant peaks obtained from the fragment isolated from C. sporogenes PA 3679 and C. sporogenes 
ATCC 15579, from m/z 900 to 2300 Da. The m/z value of each signal represents the mass of a 
protonated RNA fragment in Daltons (Da). All the fragments in the spectra were seen as doublets 
consisting of the linear fragment and the cyclic phosphate intermediates. The cyclic phosphate 
intermediates are formed during the RNaseT1 digestion: the cyclic intermediates come from the 
loss of a water molecule and thus they have a mass of 18 Da lower [70]. The peaks seen in the 
spectra were compared to the theoretical digestion and, as a first approach, it was possible to 
recognize most of the peaks expected, although in the C. sporogenes ATCC 15579 spectrum the 
cyclic forms were predominant. Also, a non-theoretically expected peak at m/z 1013.2 Da can be 
seen in both spectra. This peak corresponds to a mono-methylation in the fragment AUG 
(999.2+14). 
  Investigation of a cfr-like gene from Clostridium 
29 
 
 
Figure 15: MALDI-TOF MS spectra (m/z 900 to 2300 Da) of RNaseT1 digestion of the fragment comprising positions 
2480-2527 (E. coli numbering) of 23S rRNA from C. sporogenes PA 3679 (above) and C. sporogenes ATCC 15579 (below), 
and table of the masses of the observed signals. 
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As shown above, not all the signals are seen due to overlapping of the peaks with similar 
m/z. Hence, each region is further analyzed in more detail. In Figure 16 is shown the initial area 
correspondent to m/z 952 to 1032 Da, where the methylation at A2503 occurs. All the fragments 
in this area are represented: linear and cyclic form of UCG, which has really intense signal, because 
there are two UCG in the RNA fragment isolated; linear and cyclic form of ACG can be seen clearly 
in both spectra; as far as AUG is concerned, it can be barely seen in the spectra, probably because 
most of the fragments are methylated, and then we can see the peak corresponding to AUG mono-
methylated. If the Cfr-like protein was functioning as the Cfr methyltransferase, it would di-
methylate the adenosine at position 2503 and then a peak at m/z 1027 would be seen. However, 
as shown in Figure 16, no peaks are visible in that area. Hence, the methylation observed is probably 
caused by RlmN (rlmn gene is present in both genomes of C. sporogenes) and this methylation 
occurs at C-2 of A2503. To be sure about the methylation additional experiments have to be 
performed, such as the tandem mass spectrometry approach described by Giessing et al., where 
they use an online nanoliquid chromatography electrospray ionization tandem mass spectrometry 
(nano-LC-ESI-MSn) in order to structurally characterize the modification [21]. Finally, there is a peak 
at m/z 1018.96 that cannot be explained by the theoretical fragmentation. This fragment was 
assumed as a non-RNA fragment. Comparing the m/z of all peaks, the RNA fragments always have 
low decimals values, typical of the RNA fragments. In contrast, the peak at m/z 1018.96 has a really 
high decimal value, suggesting that this is in fact a Matrix signal. 
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Figure 16: MALDI-TOF MS spectra (m/z 952 to 1032 Da) of RNaseT1 digestion of the fragment comprising positions 
2480-2527 (E. coli numbering) of 23S rRNA from C. sporogenes PA 3679 (above) and C. sporogenes ATCC 15579 (below), 
and table of the masses of the observed signals. 
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The area comprising m/z 1257 to 1288 (Figure 17) shows undoubtedly the linear and cyclic 
forms of CUCG and UUUG. Here, the predominance of the cyclic forms in the spectrum of C. 
sporogenes ATCC 15579 is once more denoted.  
 
 
Figure 17: MALDI-TOF MS spectra (m/z 1257 to 1288 Da) of RNaseT1 digestion of the fragment comprising positions 
2480-2527 (E. coli numbering) of 23S rRNA from C. sporogenes PA 3679 (above) and C. sporogenes ATCC 15579 (below), 
and table of the masses of the observed signals. 
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Finally, the last area shown in Figure 18 (m/z 2197 to 2245) contains the cyclic and linear 
forms of CAUCCUG. The peak corresponding to the fragment CACCUCG should also be seen, 
according to the theoretical digestion, but in both spectra it is not visible. Also, a non-expected peak 
appears at m/z 2237.3. The most likely explanation is that the fragment CACCUCG is somehow 
modified and gives origin to the non-expected peak. In fact, if we look carefully to the spectra, a 
smaller peak is seen around m/z 2219 that could be associated to the linear form of CACCUCG. 
However, no cyclic form can be seen around m/z 2201, which is not consistent with what happens 
in all the other fragments. Thus, the peak around m/z 2219 can be explained as the cyclic form of 
the linear fragment at m/z 2237.3, telling us how trustable this peak can be. The non-expected peak 
at m/z 2237.3 corresponds to 2219+18. There isn’t an explanation about what modification could 
give rise to this additional 18 Da. Hence, further studies should be performed, such as tandem mass 
spectrometry (MS-MS) on the ions corresponding to the fragment CACCUCG. In this technique, the 
fragment of RNA is completely hydrolysed into its nucleoside constituents (electrospray ionisation 
– ESI), which are then identified by combined liquid chromatography and MS-MS. To locate the 
nucleotide modifications in the primary sequence, another aliquot of the RNA in question is 
digested to completion with a nucleotide-specific RNase, and the digestion mixture is analysed by 
online high performance liquid chromatography (HPLC)/ESI-MS. By comparing the observed masses 
with the ones expected from the gene sequence, RNase digestion fragments harbouring 
posttranscriptional modifications can be identified [72]. 
 
  Investigation of a cfr-like gene from Clostridium 
34 
 
 
Figure 18: MALDI-TOF MS spectra (m/z 2197 to 2245 Da) of RNaseT1 digestion of the fragment comprising positions 
2480-2527 (E. coli numbering) of 23S rRNA from C. sporogenes PA 3679 (above) and C. sporogenes ATCC 15579 (below), 
and table of the masses of the observed signals. 
 
 
 
  Investigation of a cfr-like gene from Clostridium 
35 
 
3. Conclusions  
In the first part of the project, five new constructs were made to obtain plasmids expressing 
constitutively the clcs, cfr, scfr, scac and casc genes. The expression level of Cfr and Cfr-like proteins 
was investigated but no protein bands were detected at the expected masses and it could not be 
verified by MS either (probably because we excised the wrong area of the gel). Nevertheless, MIC 
analysis showed that sCfr lowered the sensitivity to the PhLOPSA antibiotics tested, conferring a 
resistance pattern similar to the S. sciuri Cfr methyltransferase. Cfr showed lower effectiveness than 
sCfr, probably because it is not codon optimized for E. coli. ClCs did not mediate MIC changes, as 
well as sCAC and CAsC proteins, showing no Cfr methyltransferase function in E. coli. The RNA 
methylation at A2503 in 23S rRNA was checked by primer extension and the analysis showed a clear 
stop at A2503 of 23S RNA from sCfr and a weaker stop in the case of Cfr. Thus, both sCfr and Cfr 
confer decreased susceptibility to three classes of antibiotics by modification of position A2503 in 
23S rRNA from E. coli. There was no stop in the ClCs- and combined proteins-containing strains, 
which is consistent with no observed MIC changes. Thus, the Cfr-like from Clostridium sporogenes 
does not methylate E. coli 23S RNA. However, it was not possible to conclude that ClCs does not 
have a Cfr-like function and it may be able to methylate Clostridium 23S RNA but not E. coli 23S 
RNA, which should be investigated in the second part of the project. 
In the second part, the amplification of the cfr-like gene from C. sporogenes PA 3679 was 
not possible, leading to the hypothesis that the cfr-like gene is absent in this strain. In contrast, the 
amplification of the cfr-like gene from C. sporogenes ATCC 15579 was achieved. Both strains were 
exposed to representatives of the five antibiotic classes in the PhLOPSA phenotype conferred by the 
Cfr methyltransferase. MICs obtained from C. sporogenes ATCC 15579 showed lower susceptibility 
to all the PhLOPSA antibiotics tested than the presumably Cfr-lacking strain C. sporogenes PA 3679. 
Thus, the Cfr-like protein may confer some resistance to C. sporogenes ATCC 15579 or another 
mechanism, responsible for the resistance observed, is present in this strain. The function of the 
Cfr-like protein from C. sporogenes ATCC 15579 was investigated by primer extension, using C. 
sporogenes PA 3679 as a negative control. A visible but not too strong stop at A2503 of 23S RNA 
from both C. sporogenes strains was detected, which required further analysis. MALDI-TOF MS 
showed two theoretically non-expected peaks in both strains spectra. The first corresponds to a 
mono-methylation in the fragment 2503AUG2505. Since rlmN-gene is present in both strains, it 
probably corresponds to a methylation in C-2 at A2503 (m2AUG). The second peak can be explained 
by a possible modification in the fragment 2496CACCUCG2502. The spectra from both strains showed 
the same peaks, revealing that the presence of the Cfr-like protein in C. sporogenes ATCC 15579 
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does not mediate additional modification in the isolated RNA fragment comparing with the 
presumably Cfr-lacking strain C. sporogenes PA 3679. 
 
4. Future Work 
Future work could include the construction of more combinations of parts of scfr and clcs 
genes in order to investigate the lack of function of the ClCs when expressed in E. coli, and to try to 
define if parts of ClCs could be functioning as the corresponding areas of Cfr or to define which part 
prevents the function. Also, the expression of Cfr and Cfr-like proteins in E. coli should be analyzed 
because there is no visible reason or cause for inhibition or no expression. MS should be performed 
again to analyze the bands near the ones already studied in this project. Another possible direction 
would be performing a Western Blot analysis of the Cfr and Cfr-like proteins since it allows the 
detection of a specific protein. For the second part of the project, in order to ascertain the source 
of the primer extension stop, further studies should be made in the presence of antibiotics, to try 
to clarify if the resistance phenotype is inducible by its presence. In order to ascertain the position 
of the methylation at A2503, additional tandem MS should be performed to structurally 
characterize the modification. Last but not least, the supposed modification in fragment 
2496CACCUC2502 should be analysed by combined liquid chromatography and MS-MS to identify 
posttranscriptional modifications. 
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5. Materials and Methods 
5.1. Part I – Cloning of cfr and cfr-like genes in E. coli  
5.1.1. Strains and growth conditions 
The E. coli TOP10 strain was used for transformation of ligated constructs. The 
hyperpermeable E. coli AS19 strain [62] was used for MIC analysis to emphasize the observed 
effects because it is much more sensitive to antibiotics than other E. coli strains that have a 
relatively low susceptibility to many drugs. The RlmN-lacking strain E. coli JW2501-1 [65] was used 
for methylation analysis to facilitate identification of Cfr methylation by avoiding interference from 
the RlmN methylation at the same nucleotide. All strains were grown in Luria-Bertani (LB) broth 
and Luria-Agar (LA) plates at 37°C.  
 
5.1.2. Growth curves – E. coli AS19/pClCs 
An overnight culture was diluted in LB, to a final OD450 of 0.005. The cells were incubated 
at 37°C, with shaking, and induced with IPTG after 30 minutes. The final concentration of IPTG was 
0, 0.2 and 1 mM. The OD450 was measured, approximately, every 20 minutes over a period of 6 
hours until stationary phase was reached. 
 
5.1.3. Construction of plasmids encoding cfr and cfr-like genes 
The plasmid pCfrHisN, containing the wild-type cfr gene was provided by “BV group”. The 
synthetic scfr and clcs genes were designed to be codon optimized for E. coli and both were 
purchased from GenScript USA Inc.. The plasmids bearing cfr and clcs genes were constructed by 
PCR amplification of the genes from genomic DNA or synthetic genes, followed by cloning into 
plasmid pBR322 for expression of the proteins. Standard PCR amplification of the genes and vector 
(vector part with the amp gene) was performed with the proper primers (Table 6), each containing 
AvrII-CCTAGG and XhoI-CTCGAG restriction sites for cloning. The plasmid carrying scfr gene was 
only cut with AvrII and XhoI because it already had the restriction sites.  The PCRs were performed 
with NEW ENGLAND BioLabs® Inc. – Phusion® High Fidelity DNA polymerase, which includes the 
procedure and program followed.  
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Table 6: Primers and PCR conditions used to construct the plasmids encoding cfr- and ClCs- genes. The annealing 
temperature for the primers was calculated using NEB Calculator, according to the manufacturer’s instructions. 
Vector or 
gene 
Primers (5’ → 3’) PCR conditions 
pBR322 
BV431 (forward) 
TATACTCGAGGCCGGCGGCACCTCGCTA 
 
BV432 (reverse) 
TCATCCTAGGTGCCTGACTGCGTTAGCA 
Initial denaturation (98°C): 1  min; 5 initial 
cycles, denaturation (98°C): 8 sec, annealing 
(65°C): 66 sec, extension (72°C): 20 sec; 25 
cycles, denaturation (98°C): 8 sec, annealing 
(72°C): 66 sec, extension (72°C): 20 sec and final 
extension (72°C): 8 min 
cfr 
BV462 (forward) 
GGTTCCTAGGATGAATTTTAATAATAAAAC 
 
BV463 (reverse) 
TTAACTCGAGCTATTGGCTATTTTGATAAT 
Initial denaturation (98°C): 1  min; 5 initial 
cycles, denaturation (98°C): 8 sec, annealing 
(45°C): 20 sec, extension (72°C): 20 sec; 25 
cycles, denaturation (98°C): 8 sec, annealing 
(59°C): 20 sec, extension (72°C): 20 sec and final 
extension (72°C): 8 min 
clcs 
BV475 (forward) 
GATACCTAGGATGAAACAAACCAAAACCAA 
 
BV476 (reverse) 
CGCGCTCGAGTTACAGTTCATTTTCATAAC 
Initial denaturation (98°C): 1  min; 5 initial 
cycles, denaturation (98°C): 8 sec, annealing 
(49°C): 20 sec, extension (72°C): 30 sec; 25 
cycles, denaturation (98°C): 8 sec, annealing 
(72°C): 20 sec, extension (72°C): 30 sec and final 
extension: 8 min 
 
The PCR products were electrophoresed in an agarose gel (1% for the vector and 1.5% for 
the fragments) to determine the size of the fragments and were subsequently purified using Gen 
EluteTM Gel Extraction Kit (Sigma-Aldrich). After cleavage with the AvrII and XhoI enzymes (followed 
by purification using Gen Elute PCR Clean-up Kit – Sigma-Aldrich), the fragments and vector were 
ligated according to the ratio 50 fmol: 10 fmol, respectively. To calculate the concentration from 
ng/μl to fmol/μl the following formula was used: 
𝑥 𝑛𝑔 𝜇𝐿⁄  × 1015𝑓𝑚𝑜𝑙 𝑚𝑜𝑙⁄
𝑥𝑥 𝑏𝑝 × 600𝑔 𝑚𝑜𝑙 × 109𝑛𝑔 𝑔⁄⁄
=  𝑓𝑚𝑜𝑙 𝜇𝐿⁄ . Ligation 
was performed according to the following procedure (for 20μL reaction): X μL vector, Y μL fragment, 
2 μL 10 X Ligase Buffer (Roche), 1 μL T4 DNA Ligase (Roche), 1 μL of 10 mM ATP and H2O up to 20µL.  
It was incubated at 16°C overnight. The new plasmids were named pBRCfr, pBRsCfr and pBRClCs, 
according to the expressed proteins. 
The transformation of the plasmids into E. coli Top10 was carried out by the CaCl2-method: 
75 µL of an overnight culture of E. coli Top10 were added to 25 mL LB and incubated at 37°C with 
shaking until the culture reached an OD450 of 0.5. The cells (2x 10 mL) were then harvested by 
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centrifugation for 5 min at 3000g, at 4°C, and resuspended with 5 mL ice-cold 50 mM CaCl2. Once 
again, the cells were harvested by centrifugation for 5 min at 3000g, at 4°C, and resuspended in 
800 µl ice-cold 50 mM CaCl2. The cells were left on ice for at least 30 min. Transformation was 
carried out by mixing 10 ng of the plasmids with 200 µL of the competent cells. After 30 min on ice, 
heat chock at 42°C for 1.5 min, and ice again for 5 min. Then 800 µL of LB were added and the cells 
incubated at 37°C for 1 hour. Finally, the cells were centrifuged at 4000g for 1 min and the pellet 
was resuspended in 100 µL LB. All the volume was applied to LA plates, supplemented with 100 
µg/mL ampicillin. Transformants were observed after 17 h at 37°C.  
After obtaining single colonies, plasmids were isolated from these clones using the Gen 
EluteTM Plasmid Miniprep Kit (Sigma-Aldrich) and retransformed into E. coli AS19 and E. coli 
JW2501-1 for the further experiments. As negative and positive controls, cells harboring the 
plasmid pBR322 alone and pBglII were used, respectively. All three plasmid constructs were 
sequenced at the inserted gene (Eurofins MWG Operon) to verify the identity of the cloned genes. 
The transformation into E.coli AS19 was conducted using a method with minor differences, the 
MgCl2-method (first resuspension with 5 mL ice-cold 0.1 mM MgCl2 and final resuspension in 1 mL 
ice-cold 0.1 M CaCl2), and the cells were spread on plates with 50 μg/mL ampicillin instead of the 
usual 100 μg/mL.  
 
5.1.4. Construction of plasmids encoding combined parts of scfr and clcs genes 
The plasmids pBRsCfr and pBRClCs were cut with the same restriction enzyme, a double 
cutter, AflIII. The digestion products were electrophoresed in an agarose gel and purified as 
described above. Then, the fragments were ligated according with the ratio 30 fmol: 30 fmol, to 
produce two different plasmids, one containing the first part of scfr + the second part of clcs 
(pBRsCfrAflIIClCs), and the second one comprising the first part of clcs + the second part of scfr 
(pBRClCsAflIIIsCfr). The new plasmids were named pBRsCAC and pBRCAsC. The plasmids were then 
transformed as explained above.  
 
5.1.5. Growth curves – E. coli AS19/pBR322, AS19/pBRsCfr and AS19/pBRClCs  
Overnight cultures of all strains were diluted in LB, to a final OD450 of 0.005. The cells were 
incubated at 37°C, with shaking. The OD450 was measured, approximately, every 20 to 30 minutes 
over a period of 8 hours until stationary phase was reached. 
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5.1.6. Antibiotic susceptibility testing  
LB medium was inoculated with single colonies and incubated overnight and then the 
cultures were diluted to OD450 = 0.01. The strains were tested using three different antibiotics, 
tiamulin, chloramphenicol and linezolid. The antibiotic concentration ranges were: tiamulin and 
chloramphenicol 0.5 – 32 μg/mL and linezolid 1 – 64 μg/mL. Drug susceptibility testing was done in 
a microtiter plate format, where 100μl of diluted culture was mixed with 100μl of antibiotic 
solutions in a series with 2-fold concentration steps and with triplicates for each strain. The plates 
were incubated for 24 hours at 37°C and optical density values at 450 nm were measured with a 
Victor 3 plate reader (Perkin Elmer).  
 
5.1.7. SDS gel analysis  
E. coli AS19 cells harbouring the plasmids were grown at 37°C with shaking until reaching 
an OD450 of 1 and then harvested. The pellet was dissolved in 1xSDS/dithiothreitol (DTT) loading 
buffer, incubated at 95°C for 5 min, centrifuged at 12000 rpm for other 5 min and then placed on 
ice. The samples were then loaded onto a 4-12% SDS gel along with the marker (Fermentas #1811 
– Page RulerTM Plus Prestained Protein Ladder). The gel was run at 50 V for around 30 min and then 
at 180 V for approximately 70 min in Tris-Glycine-SDS (TGS) buffer. Before visualization, the gel was 
stained with Coomassie brilliant blue G and then transferred into water to decolourise.  
To isolate protein for mass spectrometry, cells from E. coli AS19, AS19/pBRCfr, 
AS19/pBRsCfr and AS19/pBRClCs were loaded onto a thicker (1 mm) and bigger (15x15 cm) SDS gel 
along with Fermentas #1811 marker (run at 24 mA for around 9 hours). After running the gel, the 
bands of interest were cut for mass spectrometry investigation, conducted by a technician from the 
Protein Research Group, another group from our department. 
  
5.1.8. Primer extension analysis 
Diluted overnight cultures of E. coli JW2501-1 cells harbouring the plasmids were grown at 
37°C, until reaching an OD450 between 0.3 and 0.4, corresponding to the time when the cells are 
in exponential phase. A volume of cells corresponding to 4 ml culture with an OD450 of 0.375 was 
harvested. RNA was subsequently extracted using Gene JET RNA Purification Kit (Thermo Scientific). 
1 µL of 4,5X Hybridization buffer (250 mM K. Hepes pH 7.0, 500 mM KCl) and 1 µL of 10 pmol/µL 
primer (Cy5-labeled, 5’–GAACAGCCATACCCTTG–3’) were added to 2.5 µL of 1600 ng of RNA. 
Samples were boiled for 2 minutes at 80°C and slowly cooled down until they reached a 
temperature of 45°C. To each sequencing reaction, one kind of ddXTP (1 μl of 100 μM, X=G, A, T or 
C) was added, resulting in four different mixtures. 0.6 µL of extension buffer (1.3 M Tris-HCl pH 8.4, 
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100 mM MgCl2, 100 mM DTT), 0.3 µL of dNTP (1.1 mM of each), 2.1 µL of water and 1.5U of reverse 
transcriptase (Roche) were then added to all samples. Samples were mixed and incubated at 42°C 
for 30 minutes. The cDNA, produced by reverse transcriptase, was precipitated by adding 20 μl 0.25 
M NaOAc pH 6.5 and 45 μl 96 % EtOH. The samples were centrifuged for 10 minutes at full speed 
and the supernatant was removed, leaving only the pellet. The pellet was washed with 70 μl 70 % 
EtOH and centrifuged at full speed for 5 minutes. The pellet was left to dry and afterwards dissolved 
in 5 μl UREA loading buffer (8 M UREA, 20 mM Tris-HCl pH 7.8, 1 mM EDTA and bromophenol blue 
dye). Before loading on the gel, the samples were incubated at 80°C for 2 minutes. The resulting 
cDNA extension products were separated on 6% polyacrylamide sequencing gel (pre-run at 45 W 
for 30 minutes) and run in 0.9 x Tris-Borate-EDTA (TBE) buffer, until bromophenol blue reached the 
bottom. The visualization was achieved by fluorescence scan with Typhoon TRIO Variable Mode 
Imager (Amersham Bioscience). 
 
5.2. Part II – Investigate the function of the Clostridium cfr-like gene 
in C. sporogenes PA 3679 and C. sporogenes ATCC 15579 
5.2.1. Growth conditions 
The strain Clostridium sporogenes PA 3679 (bougth under the name NCTC 8594) was 
obtained from Public Health England and C. sporogenes ATCC 15579 from American Type Culture 
Collection. To grow the strains, ATCC® Medium: 2107 Modified Reinforced Clostridial Agar/Broth 
(pre-reduced) was used as well as 37°C as the optimal temperature. To maintain the anaerobic 
atmosphere required for these strains, Hungate-tubes were used for broth cultures (addition of N2 
to remove O2) and the plates were incubated in an anaerobic jar with a sachet of Anaerocult A or 
AnaeroGen.  
 
5.2.2. 16S rRNA and cfr-like gene amplification 
PCR reactions were performed to amplify the 16S ribosomal RNA and the cfr-like gene. 
Proper primers were designed for all PCR reactions and the DNA was extracted using DNeasy Blood 
and Tissue Kit (Qiagen) – Pretreatment for Gram Positive Bacteria. 
Primers and PCR conditions are resumed in Table 3. The PCRs were performed with NEW 
ENGLAND BioLabs® Inc. – Phusion® High Fidelity DNA polymerase and NEW ENGLAND BioLabs® Inc. 
– Q5® High-Fidelity DNA Polymerase, which includes the procedure and program followed. All PCR 
products were measured and sent for sequencing to Eurofins MWG Operon. 
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5.2.3. Primer extension analysis 
100 µL of an overnight culture of each C. sporogenes strain were added to 10 mL of fresh 
broth and incubated at 37°C, for around 6,5h. A volume of cells corresponding to 4 ml culture with 
an OD450 of 0.375 was harvested. RNA was then extracted using the Gene JETTM RNA Purification Kit 
(Thermo Scientific), 100μl of extract were obtained and the concentration was measured by 
Nanodrop. The extract was run in an agarose gel (1.5 %) at 75 volts for about 30 minutes, to confirm 
that an isolation of total RNA was obtained (RNA from E. coli used as control). The same procedure 
described in part I was applied, but a phosphorylated primer (5’– GAACAGCCCAACCCTTG–3’) was 
used and the gel was visualized by a phosphor scan with the same equipment. 
 
5.2.4. Purification of total RNA for MALDI-TOF analysis 
1 mL of an overnight culture of each C. sporogenes strain were added to 150 mL of fresh 
broth and incubated at 37°C, for around 6h. After that, the cells were placed on ice for 10 min and 
then centrifuged at 6000 rpm, for 10 min at 4°C. The pellets were washed and resuspended in 100 
mL of cold TMN buffer (100 mM NH4Cl, 10 mM MgCl2, 50 mM Tris-HCl pH 7.5) and centrifuged again 
at 6000 rpm, for 10 min at 4°C. Another 2 mL of cold TMN buffer were added and the pellets were 
resuspended by vortexing. Then, the cells were lysed by sonication, and cell debris was removed by 
centrifugation (2 X 10 min at 4°C). Afterwards, RNA was extracted using phenol and chloroform (3 
times phenol, 1 time phenol/chloroform, 1 time chloroform). The reagent was added to the 
supernatant (1:1), vortex for 10 seconds, shaking for 3 minutes and centrifugation at full speed for 
3 minutes. After all successive extractions, the aqueous phase was precipitated with 1/10 volume 
of 3M NaOAc pH 6.5 and 3 times volume of 96% ethanol. The mixture was incubated at -20ºC for 1 
hour and centrifuged for 40 min at max speed. The pellet was washed with 1/3 volume of 70% cold 
ethanol and centrifuged again for 5 min at max speed. The pellet was left to dry at room 
temperature and finally dissolved in 40µL of water.   
 
5.2.5. Isolation of defined rRNA sequence for MALDI-TOF analysis 
To 100 pmol of RNA, 4X hybridization buffer (250 mM HEPES pH 7.5, 500 mM NH4Cl) and 
500 pmol of synthetic oligodeoxunucleotide were added. The oligodeoxunucleotide composed by 
48 nt (5’–GCCCCAGGATGCGACGAGCCGACATCGAGGTGCCAAACCTCCCCGTCG–3’) is complementary 
to the site of interest and binds to nucleotides 2480 to 2527 of C. sporogenes 23S ribosomal RNA 
(E. coli numbering). The mixture for annealing was heated at 80°C for 5 min and then cooled down 
until reach 35°C. The digestion was performed by adding 20 units of Mung bean nuclease, 1 volume 
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of Mung bean nuclease buffer (50 mM NaOAc pH 5.0 at 25°C, 30 mM NaCl, 1 mM ZnCl2), and 0.25 
µg of RNaseA to the hybridisation mixture and incubating at 35°C for 60 minutes. The reaction was 
stopped and the enzymes removed by extracting with 1 volume of phenol/chloroform. The 
RNA:DNA hybrid was precipitated with 1/10 volume of 3M NH4Ac pH 6.5 and 3 volumes of 96% 
ethanol. The mixture was placed at 0°C for 45 minutes and centrifuged at max speed for other 45 
minutes. The pellet was washed with ½ volume of 70% cold ethanol and centrifuged for 15 minutes. 
The pellet was left to dry at room temperature and dissolved in 6µL of water. To isolate the RNA 
fragment, the mixture was separated on 13% polyacrylamide gel (1:30 7 M urea). Before loading 
the sample, control (hybridization mixture without oligo) and 50 pmol of oligo, 12µL of formamide 
were added. The gel ran 75 min at 18W in 1 x Tris-Borate-EDTA (TBE) buffer. The gel was transferred 
to a solution of 1 x TBE+EtBr (0.5 µg/mL) and incubated for 30 minutes shaking. Afterwards, it was 
visualized by UV light and the band corresponding to the nuclease protected RNA sequence was 
excised. To the excised fragment cut into pieces, 120uL of 2M NH4Ac pH 5.3 were added. It was 
then placed at 4°C, shaking vigorously overnight. To the supernatant, 3 volumes of 96% ethanol 
were added. The mixture was placed at 0°C for 45 minutes and centrifuged at max speed for other 
45 minutes. The pellet was washed with ½ volume of 70% cold ethanol and centrifuged for 15 
minutes. The pellet was left to dry at room temperature and dissolved in 4µL of water. Finally, the 
RNA was digested with RNase T1 to obtain a mass fingerprint of the sequence. To 2 µL of dissolved 
rRNA, 0.5 µL of 0.5 M 3-HPA (3-Hydroxypicolinic Acid) matrix and 0.5 µL of RNase T1 (10U/µL) were 
added. The mixture was incubated at 37°C overnight. Half of the digested RNA (1.5 µL), 0.5 µL of 
0.5 M 3-HPA matrix and 0.1 µL of suspended ammonium loaded ion exchange beads were mixed 
on the target plate. The sample was left to dry and the beads removed hereafter. Spectra were 
recorded in reflector and positive ion mode on a Bruker – The new ultrafleXtreme™ mass 
spectrometer and smoothed using the software ‘m/z’ (FlexAnalysis version 3.4). 
 
5.2.6. Antibiotic susceptibility testing  
ATCC® Medium: 2107 Modified Reinforced Clostridial broth was inoculated with 100 µL 
cells of both C. sporogenes strains and incubated overnight at 37°C. The cultures were diluted to 
OD450 = 0.01 to perform a Minimum Inhibitory Concentration (MIC) analysis. C. sporogenes PA 3679 
and C. sporogenes ATCC 15579 were tested using nine different antibiotics: tiamulin, 
chloramphenicol, linezolid, clindamycin, synercid, erythromycin, valnemulin, kanamycin and 
streptomycin. The antibiotic concentration ranges were: tiamulin 2 – 128 μg/mL, chloramphenicol 
0.125 – 8 μg/mL, linezolid 0.125 – 8 μg/mL, clindamycin 0.125 – 8 μg/mL, synercid 0.25 – 16 μg/mL, 
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erythromycin 0.125 – 8 μg/mL, valnemulin 2 – 128 μg/mL, kanamycin 0.125 – 8 μg/mL and 
streptomycin 0.125 – 8 μg/mL. Drug susceptibility testing was done as described in part I, but the 
plates were incubated in an anaerobic jar.  
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